Immuneering Corporation

NASDAQ:IMRX

Biotechnology

Healthcare
$3.50 -0.14%

-$0.01 today

Market cap
$226.67M
Beta
0.38
P/E (TTM)
-3.6
EPS (TTM)
-$1.24
52W Low $2.29High $10.08

Volume 0.73M

Average 1.38M

IMRX Total Debt

Short-term and long-term borrowings combined.

Immuneering CorporationNASDAQ: IMRX

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt rises 91265.7% from a year ago

Total debt stood at $3.73B at the end of Q1 FY2026, up 91265.7% from a year earlier and up 97436.3% from the prior quarter. Over 3 fiscal years it compounded at -7.6% a year.

Context

  • Total debt amounted to 1.7% of total assets at the end of Q1 FY2026, down 6.3 pp from a year earlier.
  • Total debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps rising in the next quarterly balance sheet after a +91265.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.73B+97436.3% QoQ
Last fiscal yearDec 2025
$3.82M-8.1% YoY
Year agoMar 2025
$4.08M+91265.7% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+91265.7%——
1 year-8.1%——
3-year CAGR-7.6%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
3.82M USD
Year-over-year change
-8.1%
4-year CAGR
-8.1%

Total Debt vs competitors

How IMRX compares with its peers on the latest reported figures

  • IMRX's Mar 2026 total debt of $3.73B is the highest of the 11 companies compared; the peer median is $26.43M.
  • Its year-over-year change of +91265.7% is the highest of 10, against a peer median of -12.7%.
  • Total debt amounts to 1.7% of total assets for IMRX, versus a peer median of 15.5%.
IMRX Competitors Peer median
Total Debt for IMRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMRXImmuneering CorporationMar 2026$3.73B +91265.7%-7.6%1.7%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$186.62M -13.7%+96.0%59.3%
HUMAHumacyte, Inc.Mar 2026$65.9M +315.8%+9.0%59.6%
TRDAEntrada Therapeutics, Inc.Mar 2026$49.75M -12.7%+25.2%14.8%
FHTXFoghorn Therapeutics Inc.Mar 2026$41.99M +20.5%-7.1%18.9%
NAUTNautilus Biotechnology, Inc.Mar 2026$28.87M -1.6%-0.3%16.2%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$23.99M -43.8%-35.9%9.8%
PYXSPyxis Oncology, Inc.Mar 2026$18.26M -8.0%-0.4%28.4%
TNYATenaya Therapeutics, Inc.Mar 2026$10.12M -21.6%-10.5%7.5%
ASMBAssembly Biosciences, Inc.Mar 2026$2.49M -17.5%-8.8%1.1%
ZURAZura Bio LimitedMar 2026$0 ——0.0%
Peer median (excluding IMRX) $26.43M-12.7%-0.4%15.5%

Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents74.89M72.64M59.41M36.14M128.65M
Short-term Investments74.31M32.89M26.26M044.19M
Net Receivables246.04K12.42K000
Inventory00000
Other Current Assets03.21M3.42M3.44M3.41M
Total Current Assets152.33M108.75M89.08M39.59M176.25M
Property, Plant & Equipment (Net)6.13M5.78M5.4M4.79M4.26M
Goodwill6.7M6.69M6.69M6.69M6.69M
Intangible Assets439K408.95K379.68K350.41K321.15K
Long-term Investments996.56K0000
Tax Assets00000
Other Non-current Assets102.13K743.7K1.03M1.3M44.47M
Total Non-current Assets14.37M13.62M13.5M13.13M55.74M
Total Assets166.7M122.37M102.58M52.71M231.99M
Account Payables1.39M3.15M2.11M1.96M1.54M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities2.92M3.65M3.89M3.82M4.54M
Total Current Liabilities5.63M8.05M7.85M7.5M10.07M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities5.09M4.46M4.16M3.82M3.43M
Total Liabilities10.72M12.52M12.01M11.33M13.5M
Common Stock26.32K26.42K29.27K31.05K64.65K
Retained Earnings(59.27M)(109.79M)(163.26M)(224.3M)(280.32M)
Accumulated OCI(49.01K)(30.12K)(778)081.33K
Other Stockholders Equity00010
Minority Interest00000
Total Equity155.98M109.85M90.58M41.39M218.48M
Total Debt5.36M4.84M4.46M4.16M3.82M
Net Debt(69.52M)(67.8M)(54.94M)(31.98M)(124.82M)

Immuneering Corporation

NASDAQ:IMRX

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.